Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection by unknown
RESEARCH Open Access
Combination effects of ribavirin and
interferons on severe fever with
thrombocytopenia syndrome virus infection
Masayuki Shimojima*, Shuetsu Fukushi, Hideki Tani, Satoshi Taniguchi, Aiko Fukuma and Masayuki Saijo
Abstract
Background: Severe fever with thrombocytopenia syndrome (SFTS) is an acute infectious disease caused by SFTS
virus and characterized by a high case fatality rate. Currently, there is no effective therapy for the disease. While the
administration of ribavirin does not improve the case fatality rate or viral load in patient blood, it can inhibit viral
infection in vitro.
Methods: Vero cells were pre-treated with interferons (IFNs) α, β, and γ alone and in combination with ribavirin
drugs and inoculated with SFTS virus. Three days later, supernatants were harvested and subjected to virus titration.
An unpaired t-test was used for statistical analysis of the drugs’ effects.
Results: While the effects of IFNγ at high concentrations were slightly weaker than those of the other IFNs, all IFNs
showed dose-dependent inhibitory effects. The combined usage of IFNs with ribavirin at 90 % effective
concentrations showed large inhibitory effects, with over a 3 log10 reduction in viral titers.
Conclusions: The combined usage of one of type-I/II IFNs with ribavirin drastically reduced SFTS virus infection and
therefore may be useful in the treatment of SFTS.
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Background
Severe fever with thrombocytopenia syndrome (SFTS)
is a recently-identified tick-born infectious disease
characterized by fever, gastrointestinal symptoms,
thrombocytopaenia, leukopaenia, and elevated levels of
liver enzymes in the peripheral blood [1, 2]. Multiple
organ failure and neurologic manifestations are often
observed in severe cases [3–5]. The case fatality rate is
up to 10 % [6]. The causative agent of the disease is
SFTS virus (family Bunyaviridae, genus Phlebovirus),
the discovery of which was reported in 2011 [1, 2].
Currently, no vaccines, therapies, or drugs have proven
to be effective against the disease.
It has been reported that SFTS patients treated with
ribavirin, plasma exchange, antibiotics, or steroids have
recovered [7–11]; however, these reports are deemed to
be inconclusive because none of the treatments have been
tried with a sufficient number of patients. Liu et al. [12]
reported the effects of ribavirin (1-β-D-ribofuranosyl-
1,2,4-triazole-3-carboxamide), a guanosine analogue with
broad antiviral activities [13], in the treatment of a total
of 311 patients, roughly half of whom did not receive
ribavirin. In that study, the daily intravenous injection
of 500 mg of ribavirin did not significantly affect the
case fatality rate or platelet counts and viral load in
blood [12], indicating that ribavirin is not effective against
SFTS at that dose. However, ribavirin apparently shows an
anti-SFTS virus effect in vitro [14]. Thus, a higher dose of
ribavirin or a different drug/strategy is likely to be necessary
in the treatment of SFTS.
In the present study, we examined the effects of inter-
ferons (IFNs) alone and in combination with ribavirin on
SFTS virus infection in vitro. The combined usage of IFNs
with ribavirin showed large inhibitory effects, suggesting
their usability in SFTS treatment.* Correspondence: shimoji-@nih.go.jpDepartment of Virology I, Chief, Special Pathogens Laboratory, National
Institute of Infectious Diseases, 4-7-1 Gakuen, Musashimurayama, Tokyo
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Results
Effects of IFNs on SFTS virus infection
Viral titers obtained from Vero cells, which were inoculated
in the absence/presence of indicated concentrations of
IFNs, are shown in Fig. 1. Although statistically significant
inhibitory effects were observed at 50–5,000 U/ml for IFNα
and β and 20–2,000 ng/ml for IFNγ, the reduction of viral
titers by IFNγ was lower than that by IFNα and β, especially
at higher concentrations (Fig. 1a, b, c). Reduction curves
were used to calculate 90 % and 99 % effective concentra-
tions (EC90 and EC99), the drug concentrations at which
viral titers were 1 and 2 log-reduced, respectively. The EC90
values of IFNα, β, and γ were 29 U/ml, 24 U/ml, and 12
ng/ml, respectively. The EC99 values of IFNα, β, and γ were
210 U/ml, 160 U/ml, and >2,000 ng/ml, respectively.
Cytotoxicity was examined by measuring cell viability
after cell culture in the presence of drugs without virus
inoculation. As shown in Fig. 1, >70 % viability was
maintained at all examined concentrations of IFNα and
β (Fig. 1a, b), while at 200 and 2,000 ng/ml of IFNγ, cell
viability was reduced to 60 % (Fig. 1c). These findings
indicate, with the exception of high concentrations of
IFNγ (200 and 2,000 ng/ml), the reduced titers of SFTS
virus in the presence of IFNs (Fig. 1).
Combination effects of IFNs and ribavirin
Using its reduction curve (which has already been
reported) [14] (Fig. 1d), the EC90 of ribavirin in the inhib-
ition of SFTS virus infection was calculated as 43 μg/ml.
The combination effects of each of the IFNs with ribavirin
Fig. 1 Anti-SFTS virus effects and cytotoxicity of IFNs and ribavirin. To measure effects of IFNs on SFTS virus infection, Vero cells were
inoculated with SFTS virus SPL030 strain in the presence of indicated concentrations of IFNα a, β b, or γ c. Titers of supernatants at 3 days
post-inoculation are shown in blue. Results are means ± standard deviation obtained from three independent experiments (n = 3). To measure
cytotoxicity of IFNs, viability of Vero cells cultured in the presence of IFNα a, β b, or γ c was measured by use of WST-1 reagent. Cell viability
was calculated as follows: (absorbance of cells in the presence of the drug – absorbance of no cells in the presence of the drug) / (absorbance
of cells in the absence of the drug – absorbance of no cells in the absence of the drug) × 100 (%). Experiments were performed in triplicate and
means ± standard deviation (n = 3) which are shown in red. Effects and cytotoxicity of ribavirin d were calculated from the data reported previously
[14] to make comparison with those of IFNs easy. Statistical analysis (unpaired t-test in comparison with data from no drug) was performed only for
data from anti-SFTS virus effects of IFNs and ribavirin. *,P < 0.05; **,P < 0.01
Shimojima et al. Virology Journal  (2015) 12:181 Page 2 of 5
were examined at concentrations of their respective EC90
values. At the same time, the single effects of each drug
were also examined (Fig. 2a). As expected, when used
alone, each drug showed a nearly 1-log reduction of viral
titer at its EC90 (IFNα, 0.75 log; IFNβ, 0.58 log; IFNγ, 0.83
log; and ribavirin, 1.0 log). Viral titers were greatly reduced
by the combined usage of IFNα-ribavirin (3.6 log), IFNβ-
ribavirin (3.2 log), and IFNγ-ribavirin (3.4 log). Differences
between the effects of the combined usage and those of
the single usage were statistically significant (P < 0.01,
unpaired t-test). The combination effects in the reduction
of viral titers were also examined among the three IFNs
(α-β, 1.0 log; α-γ, 2.2 log; and β-γ, 2.5 log). The results of
triple or quadruple combinations of IFNs and ribavirin,
which showed greater inhibitory effects on SFTS virus
infection than single- or double-combination-usage of the
drugs, are indicated in Fig. 2a.
The examination of cytotoxicity in the combination
effect study revealed that >70 % viability was maintained
in all combinations (Fig. 2b), while some combinations
showed statistically significant difference in comparison
with control (no drug) (unpaired t-test).
Discussion
The combined usage of two or more drugs drastically
reduces growth of hepatitis C virus and human
immunodeficiency virus (HIV) in vitro and has
improved the treatment of both diseases [15, 16]. In
the treatment of hepatitis C, the initial drug combination
was of broad-spectrum anti-viral agents, IFN and ribavirin.
Treatment is now shifting to a combination of IFN and a
specific antiviral drug (or drugs), or a combination of
specific antiviral drugs [15]. In HIV, the initial efficient
combination for treatment was from HIV-specific drugs –
in principal, this has not changed, even in recent treatment
regimens [16]. While specific antivirals have not yet
been developed for the severe acute respiratory
syndrome and Middle East respiratory syndrome
(MERS) coronaviruses, the combination of IFN and
ribavirin has been shown to be effective in both in
vitro and in vivo experiments [17–20], and, in the case
of MERS, in the treatment of patients [21, 22].
In the present study, the single usage of ribavirin [14]
or IFN was shown to significantly reduce the growth of
the SFTS virus. Furthermore, it was shown that the
combined usage of these drugs at low dosages resulted
in large inhibitory effects in vitro. When used singularly,
for example, approximately 123 μg/ml of ribavirin [14],
500 U/ml of IFNα, 500 U/ml of IFNβ, or more than 2 μg/
ml of IFNγ was necessary to achieve a 3-log reduction of
viral growth. In contrast, a combination of 43 μg/ml of
ribavirin and either 29 U/ml of IFNα, 24 U/ml of IFNβ, or
12 ng/ml of IFNγ resulted in a >3-log reduction of viral
growth. A ribavirin concentration of 43 μg/ml in blood
might not be achievable in humans, because the drug
reaches a peak serum concentration of 39 μg/ml with
doses as high as 2,400 mg injected intravenously [23].
However, in the present study, we used Vero cells, in which
higher concentrations of ribavirin are required to inhibit
the growth of SFTS virus (and many other viruses) [14],
than in other cell types [24, 25], probably due to insufficient
phosphorylation of ribavirin to its active triphosphate form
in the cell line [26]. Therefore, the administration of high
ribavirin doses such as 2,400 mg might show large
inhibitory effects against SFTS virus when combined
with IFNs. Although the IFNs used in the present study
were research-use-only, a concentration of 100-750 U/
ml has been observed after the intravenous injection of
3 × 107 U of human-use-approved IFNs [27, 28], which
Fig. 2 Anti-SFTS virus effects and cytotoxicity of combinations of
ribavirin/IFNs. The anti-viral effects a and cytotoxicity b of ribavirin/IFNs
were measured as described in Fig 1. Concentrations of the drugs used
were ribavirin 43 μg/ml, IFNα 29 U/ml, IFNβ 24 U/ml, and IFNγ 12 ng/ml,
EC90 of each drug in the inhibition of SFTS virus infection. Experiments
were performed in triplicate and means ± standard deviation are shown
(n= 3). *,P< 0.05; **,P< 0.01 (unpaired t-test in comparison with data
from no drug)
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are more than 3 times higher than the IFN concentra-
tions required to reach the EC90 of the SFTS virus in
vitro. Thus, the combined usage of ribavirin and IFNs
at acceptable dosages might result in a large reduction
of SFTS virus infection in vivo and could therefore be
an effective therapy for the treatment of SFTS patients.
Because SFTS virus has been shown to suppress cellular
IFN responses [29, 30], the treatment of patients with
drugs including IFNs perhaps should be initiated soon
after diagnosis of SFTS is done.
In comparison with the combination effects of a single
IFN with ribavirin at their respective EC90, the combination
effects of IFNs without ribavirin on SFTS virus infection,
especially the effects of IFNα and β, were small. However,
such small combination effects among the IFNs had been
expected due to the following reasons: (i) although precise
mechanism (s) by which ribavirin affects SFTS virus
replication is unclear, ribavirin and IFNs likely work inde-
pendently of each other [13]; (ii) IFNα and β are type-I
IFNs and completely share the receptors that transduce
intracellular signals; and (iii) IFNγ is a type-II IFN and
partially shares molecules for signal transduction with
type-I IFNs [31]. The results, however, strongly suggest
that drugs which inhibit SFTS virus proliferation by mech-
anisms different to those of IFNs/ribavirin could be candi-
date drugs to be used in combination with IFNs/ribavirin
in the treatment of SFTS patients. Further studies may
elucidate SFTS virus-specific inhibitors and/or neutralizing
antibodies [32] for SFTS therapy.
Conclusion
The combined usage of one of types I/II IFNs with ribavirin
drastically reduced SFTS virus infection and therefore may
be useful in the treatment of SFTS.
Methods
Cells, virus, and virus titration
Monkey kidney-derived Vero cells (ATCC, CCL-81) were
cultured at 37 °C in Dulbecco’s modified Eagle’s medium
(DMEM; Sigma) supplemented with 5 % heat-inactivated
fetal calf serum (FCS) (Sigma) and antibiotics (Pen Strep,
Gibco). Isolation of the Japanese SFTS virus strain SPL030
has been reported [33] and virus titration were performed
as described previously [14].
Effects of drugs on virus infection
Ribavirin, provided by Yamasa-Shouyu Co., Ltd. (Choshi,
Japan), was dissolved in phosphate-buffered saline at a
concentration of 100 mg/ml. IFNα (universal Type I
IFN, PBL InterferonSource), β (human IFN beta 1a,
PBL InterferonSource), and γ (rhIFNγ, R & D Systems)
were dissolved in DMEM supplemented with 2 % FCS
at 500,000 U/ml, 500,000 U/ml, and 200 μg/ml,
respectively. For treatment of cells, these drugs were
further diluted with cell culture medium at indicated
concentration (s), alone or in indicated combinations. Cells
were pre-treated with drugs at indicated concentrations for
1 h. One hundred TCID50 of SFTS virus was added to the
culture without removal of the drugs, and then cultured for
3 days. Culture supernatants were harvested and subjected
to virus titration [14].
Drug cytotoxicity
Cytotoxicity of drugs against Vero cells was measured
as described previously [14]. Cells were cultured for 3
days in the presence or absence of the drugs without
virus inoculation, and cell viability was measured
using the cell proliferation reagent WST-1 (Roche)
according to the manufacturer’s protocol. Cell viability
was calculated as follows: (absorbance of cells in the
presence of the drug - absorbance of no cells in the
presence of the drug)/(absorbance of cells in the
absence of the drug - absorbance of no cells in the
absence of the drug) × 100 (%).
Statistics
An unpaired t-test was used for statistical analysis of the
drugs’ effects.
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